Vote Scores
Filings read through

How funds voted at Akero Therapeutics, Inc.

Filers reporting
373, year to 30 June 2026
Latest meeting on file
Meetings on file
3

In the year to 30 June 2026, 373 filers on Form N-PX reported votes at Akero Therapeutics, Inc.. The votes fall in 2 meetings. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 549 marks to the ballot items, each with or against management. 92.2% of the marks are with management.

On say-on-pay, 1 of the 3 reporting filers that marked the item voted against management. This is 33.3% of the filers. Of the reported shares, 23.4% went against management. The median of the 3,799 companies on this site with a say-on-pay item is 6.6% of filers and 2.9% of reported shares.

By filers reporting in the year to 30 June 2026, Akero Therapeutics, Inc. was number 1,634 of 11,972 companies with a page and votes in that year. The number of filers reporting at Akero Therapeutics, Inc. rose by 1.4% from the year to 30 June 2025 to the year to 30 June 2026. At the companies on this site with filers in both years, the total of filers reporting rose by 6.0%. In all seasons on file, category SECTION 14A SAY-ON-PAY VOTES is 40.4% of the vote records at Akero Therapeutics, Inc.. At all companies on this site, it is 12.3%.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 2 Dec 2025

370 filers reported votes at this meeting in the year to 30 June 2026. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

  1. Item 1: Advisory vote on executive pay (say-on-pay)

    6 vote records from 4 filers. 1 of the 3 filers that marked the item voted against management. 1 filer gave no management mark.

  2. Item 2: Advisory vote on pay tied to a merger or sale

    537 vote records from 366 filers. 34 of the 338 filers that marked the item voted against management. 28 filers gave no management mark.

    • Positions of 44 fund families
    • For 39
    • Against 5
    • Against management 5
  3. Item 3: EXTRAORDINARY TRANSACTIONS: management items

    The company's items in this category are shown together, because filers word and number them differently.

    189 vote records from 95 filers. 0 of the 94 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 37 fund families
    • For 37
  4. Item 4: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    243 vote records from 112 filers. 8 of the 112 filers that marked the item voted against management.

    • Positions of 39 fund families
    • For 36
    • Against 3
    • Against management 3

Positions of the fund families at the meeting of 2 Dec 2025

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Akero Therapeutics, Inc., meeting of 2 Dec 2025Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familyMerger pay
AllianceBernsteinAgainst, against management
AllspringFor
American CenturyFor
BairdFor
BlackRock and iSharesFor
BNY MellonFor
Brighthouse FundsFor
Charles SchwabFor
Columbia ThreadneedleFor
DimensionalFor
DWSFor
EquitableFor
FidelityFor
First TrustFor
Franklin TempletonFor
Global XFor
Goldman SachsFor
Guggenheim and RydexFor
Hartford FundsFor
InvescoFor
J.P. MorganAgainst, against management
Jackson National fundsFor
Janus HendersonFor
John Hancock and ManulifeFor
Lincoln FinancialFor
Macquarie and Delaware FundsFor
MassMutualFor
Morgan Stanley, Eaton Vance and CalvertFor
NationwideFor
Natixis and Loomis SaylesFor
Neuberger BermanFor
Northern Trust and FlexSharesAgainst, against management
Nuveen and TIAAAgainst, against management
Pacific Life fundsFor
PGIM and PrudentialFor
PrincipalFor
ProShares and ProFundsFor
Russell InvestmentsFor
SEIFor
State Street and SPDRFor
T. Rowe PriceFor
VanguardFor
Victory CapitalFor
VoyaAgainst, against management

Every meeting on file

Meetings of Akero Therapeutics, Inc., from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 2026370433.3%
year to 30 June 202536736.5%
year to 30 June 2024304413.1%

Say-on-pay, season by season

Say-on-pay at Akero Therapeutics, Inc.: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 202637333.3%23.4%
year to 30 June 20253686.5%0.6%
year to 30 June 202430513.1%4.3%
Akero Therapeutics, Inc. and the median of companies on this site, year to 30 June 2026
Say-on-payThis companyMedian of companies on this site
Filers against management33.3%6.6%
Reported shares against management23.4%2.9%

The median covers 3,799 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at Akero Therapeutics, Inc. by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS1,16230.3%
SECTION 14A SAY-ON-PAY VOTES1,55040.4%
AUDIT-RELATED47512.4%
EXTRAORDINARY TRANSACTIONS1894.9%
CORPORATE GOVERNANCE45912.0%

The record at the SEC

Each link loaded on .

Cite this page

Vote Scores. How funds voted at Akero Therapeutics, Inc.. https://votescores.com/company/akero-therapeutics-inc/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of Akero Therapeutics, Inc. are on file?
3 meetings are on file, from 7 Jun 2024 to 2 Dec 2025. 3 meetings have 20 or more reporting filers and have their own page.
Did filers report proposals from security holders at Akero Therapeutics, Inc.?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2026. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. Akero Therapeutics, Inc. reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Akero Therapeutics, Inc., grouped by company. The name is the most common spelling among filers. The filers wrote the filings. Filings read through .